Name: 글로벌 시장 동향
SKU: CD3373
Availability: InStock

보고서 요약(국문)

보고서 개요
전 세계 림프종 검사 시장은 2023년 85억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 11.3%의 성장률을 기록하며 2031년에는 196억 3천만 달러에 이를 것으로 예상됩니다.
림프종은 면역 체계를 공격하는 혈액암의 일종입니다. 특히 면역 체계의 중요한 구성 요소인 림프구라는 백혈구를 공격합니다. 림프종은 림프계 암 또는 림프관암이라고도 불립니다. 림프종에서는 림프구의 발달이 매우 불균형해집니다. 림프구가 제대로 기능하지 못하고 통제되지 않은 채 증식하는 경향이 있습니다.
림프종에는 호지킨 림프종과 비호지킨 림프종 두 가지 주요 유형이 있습니다. 두 유형 모두 림프구를 공격합니다. 영국에서는 매년 14,000명 이상이 림프종 진단을 받고 있으며, 이는 가장 흔한 혈액암입니다. 림프종의 흔한 증상 중 하나는 덩어리입니다. 이는 부어오른 림프절(림프선)입니다. 목, 쇄골, 겨드랑이, 사타구니 또는 기타 신체 부위에 통증 없는 부기가 생길 수 있습니다. 부어오른 림프절은 장기를 압박하여 흉통, 기침, 호흡곤란 또는 복통을 유발할 수 있습니다.
시장 동향: 성장 동력
림프암 발병률 증가
전 세계 림프암 검사 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 림프암 발병률의 증가가 시장 성장을 견인하고 있습니다.
예를 들어, 2024년 1월 미국 암 협회에서 발표한 기사에 따르면, 비호지킨 림프종(NHL)은 미국에서 가장 흔한 암 중 하나로 전체 암의 약 4%를 차지합니다. 약 80,620명(남성 44,590명, 여성 36,030명)이 NHL 진단을 받을 것으로 추정되며, 여기에는 성인과 소아가 모두 포함됩니다.

림프종으로 인해 매년 약 20,140명이 사망할 것으로 추산됩니다(남성 11,780명, 여성 8,360명). 남성의 경우 평생 림프종에 걸릴 확률은 약 42분의 1이고, 여성은 약 52분의 1입니다. 그러나 개인의 발병 위험은 여러 위험 요인에 의해 영향을 받을 수 있습니다. 림프종은 어느 연령에서든 발생할 수 있으며, 특히 소아, 청소년, 젊은 성인에게서 흔한 암 중 하나입니다. 하지만 림프종 발병 위험은 평생에 걸쳐 증가하며, 처음 진단을 받는 환자의 절반 이상이 65세 이상입니다.
제한 요인
높은 검사 비용, 부족한 의료 인프라, 숙련된 전문가 부족, 새로운 기술 승인을 위한 엄격한 규제 요건 등이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 림프종 검사 시장은 검사 유형, 질병 유형, 최종 사용자, 지역별로 세분화됩니다.

CT 스캔 및 PET 스캔 부문은 전 세계 림프종 검사 시장 점유율의 약 43.8%를 차지했습니다.
CT 스캔 및 PET 스캔 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 부문에서는 기술 발전과 민간 제조업체의 연구 개발 투자 증가가 시장 성장을 견인할 것입니다.
림프종은 여러 부위에 동시에 영향을 미칠 수 있습니다. 전신 PET/CT는 골수, 간, 비장과 같이 림프종에 영향을 받은 부위를 찾아낼 수 있습니다. 이는 림프종의 병기 설정 및 재설정에 가장 정확한 영상 진단 방법이며, 치료 반응 및 암 재발에 대한 후속 평가를 위한 기준점을 제공합니다. PET는 양전자 방출 단층 촬영의 약자입니다. 이를 통해 신체의 어느 부위가 림프종에 영향을 받았는지 더욱 명확하게 파악할 수 있습니다.
플루오로데옥시글루코스(FDG)는 PET 스캔에 가장 흔히 사용되는 방사성 추적자입니다. 영상 처리 기술, 표적 윤곽 설정 방법론, 생물학적 유도 방사선 치료 및 PET 적응 치료를 위한 PET 유도 프로토콜은 이와 관련하여 중요한 요소입니다. PET/CT 스캔에서 PET와 컴퓨터 단층 촬영(CT)을 통합하면 F-플루오로-d-글루코스의 축적을 통해 병변의 정확한 위치를 파악할 수 있습니다. PET는 CT나 MRI와 같은 기존 영상 진단법에 비해 림프절 전이 진단에서 우수한 신뢰도를 보여주며, 유용한 비침습적 진단 도구로 자리매김하고 있습니다.
시장 지역별 점유율
북미는 전 세계 림프암 검사 시장의 약 42.1%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 림프암 발병률 증가, 기술 발전, 그리고 사람들의 인식 제고가 시장 성장을 견인하고 있습니다.

예를 들어, 2024년 6월 로슈는 EU CE 마크를 인정하는 국가에서 체외 진단 검사인 Ventana Kappa 및 Lambda Dual ISH mRNA Probe Cocktail assay를 출시했습니다. Ventana B세포 림프종 진단 검사는 Kappa mRNA와 Lambda mRNA를 정성적으로 검출하도록 설계되었습니다. 이 검사는 포르말린 고정 파라핀 포매(FFPE)된 인간 골수 및 림프 조직에서 B세포 림프종과 형질세포 신생물의 존재를 검출합니다.
검사의 민감도가 향상되어 단일 조직 슬라이드에서 60가지 이상의 B세포 림프종 및 형질세포 신생물 아형을 평가할 수 있습니다. 또한 소량의 생검 조직과 포르말린 고정 조직에서도 검사를 수행할 수 있으므로, 특히 림프종이 처음 의심되지 않았던 경우처럼 신선한 조직 샘플을 확보하기 어려운 상황에서 신선한 조직 샘플의 필요성을 줄여줍니다.
더욱이 캐나다 암 협회에 따르면, 매년 약 11,700명의 캐나다인이 비호지킨 림프종 진단을 받을 것으로 추정됩니다. 캐나다에서는 3,100명이 비호지킨 림프종으로 사망할 것입니다. 남성의 경우 6,600명이 비호지킨 림프종 진단을 받고 1,800명이 사망할 것이며, 여성의 경우 5,100명이 비호지킨 림프종 진단을 받고 1,300명이 사망할 것입니다.
시장 세분화
검사 유형별
감시 림프절 생검
혈액 검사
CT 스캔 및 PET 스캔
기타
질병 유형별
비호지킨 림프종
호지킨 림프종
최종 사용자별
병원
진단 센터
연구 및 교육 기관
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
남미
브라질
아르헨티나
기타 남미 지역
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 환경
전 세계 림프암 검사 시장의 주요 업체로는 GE Healthcare, Siemens Healthineer, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman 등이 있습니다. Coulter, Myriad Genetics, Ambry Genetics, Bio-Rad Laboratories 등이 주요 기업입니다.
주요 개발 사항
2024년 3월, SCOR는 암 및 기타 중증 질환 환자를 위한 보장 범위를 확대하는 것을 목표로 하는 그룹의 생체 인식 위험 계산기 시리즈에 새롭게 추가된 Vitae 림프종 위험 계산기를 출시했습니다.
2023년 11월, Roswell Park는 첨단 고속 혈액암 검사인 PanHeme을 출시했습니다. PanHeme은 차세대 유전자 시퀀싱 기술을 사용하여 백혈병, 림프종과 같은 혈액암을 진단하고 72시간 이내에 수백 개의 유전자 변이를 식별하는 검사로, 현재 분자 검사에 소요되는 3~4주 대기 시간에 비해 획기적인 개선입니다.
보고서 구매 이유
검사 유형, 질병 유형, 최종 사용자 및 지역별 글로벌 림프종 검사 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해. 트렌드 분석 및 공동 개발을 통해 사업 기회를 파악하세요.
모든 세그먼트를 포함한 글로벌 림프암 검사 시장의 다양한 데이터 포인트가 담긴 엑셀 데이터 시트가 제공됩니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑이 엑셀 파일로 제공됩니다.
글로벌 림프암 검사 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지 분량입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Lymph Cancer Testing Market reached US$ 8.5 billion in 2023 and is expected to reach US$ 19.63 billion by 2031, growing at a CAGR of 11.3% during the forecast period 2024-2031.
Lymphoma is a type of blood cancer that affects the immune system. It specifically affects white blood cells called lymphocytes, an important part of the immune system. Lymphoma is also called a cancer of the lymphatic system, or lymphatic cancer. In lymphoma, the development of the lymphocytes becomes very uneven. The lymphocytes don’t work properly and tend to multiply out of control.
There are two main types of lymphoma, Hodgkin lymphoma and non-Hodgkin lymphoma. Both types affect the lymphocytes. Over 14,000 people are diagnosed with lymphoma each year in the UK, making it the most common blood cancer. A common lymphoma symptom is lumps. These are swollen lymph nodes (glands). One may get painless swellings on the neck, collarbone, armpit, groin, or other body parts. Some swollen lymph nodes can press on organs and cause pain in the chest, coughing, breathlessness, or pain in the stomach area.
Market Dynamics: Drivers
Increasing prevalence of lymph cancers
The demand for the global lymph cancer testing market is driven by multiple factors. The rising prevalence of lymph cancers propels the market growth.
For instance, according to an article published by the American Cancer Society in January 2024, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. It is estimated that about 80,620 people (44,590 males and 36,030 females) will be diagnosed with NHL. This includes both adults and children.
It is estimated that about 20,140 people will die from this cancer (11,780 males and 8,360 females). Overall, the chance that a man will develop NHL in his lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. However, each person’s risk can be affected by several risk factors. NHL can occur at any age. It is one of the more common cancers among children, teens, and young adults. Still, the risk of developing NHL increases throughout life, and more than half of people are 65 or older when they are first diagnosed.
Restraints
Factors such as high cost associated with the testing, lack of healthcare infrastructure, shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.
Market Segment Analysis
The global lymph cancer testing market is segmented based on test type, disease type, end-user, and region.
The segment CT scan and PET scan accounted for approximately 43.8% of the global lymph cancer testing market share
The CT scan and PET scan segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.
Lymphoma can affect different areas at the same time. Whole-body PET/CT can find sites affected by lymphoma such as the bone marrow, liver, and spleen. It’s the most accurate imaging method for staging and re-staging lymphoma and provides a baseline for subsequent evaluation of therapy response and cancer recurrence. PET stands for positron emission tomography. This can help to give a clearer picture of which areas of the body are affected by lymphoma.
Fluoro-deoxy-glucose (FDG) is the radiotracer most often used in PET scans. The image processing techniques, target delineation methodologies, and PET-guided protocols for biologically guided radiation therapy and PET-adaptive therapy are important factors in this regard. The integration of PET with computed tomography (CT) in PET/CT scans enables precise localization of lesions through the accumulation of F-fluoro-d-glucose. PET exhibits superior reliability in diagnosing lymph node metastases compared to conventional imaging modalities such as computed tomography or MRI, positioning it as a valuable non-invasive diagnostic tool.
Market Geographical Share
North America accounted for approximately 42.1% of the global lymph cancer testing market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of lymph cancer, technological advancements, and growing awareness among people, in this region, help to propel the market.
For instance, in June 2024, Roche launched an in vitro diagnostic assay, Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries that accept the EU CE mark. The Ventana B-cell lymphoma diagnostic assay is designed to qualitatively detect Kappa mRNA and Lambda mRNA. The test detects the presence of B-cell lymphomas and plasma cell neoplasms in formalin-fixed, paraffin-embedded (FFPE) human bone marrow and lymphoid tissue.
The increased sensitivity of the test allows for the assessment of more than 60 subtypes of B-cell lymphoma and plasma cell neoplasms on a single tissue slide. The test can also be performed on small biopsies and formalin-fixed tissue, thereby reducing the need for a fresh tissue sample, which may not be available, especially if lymphoma was not originally suspected.
Moreover, according to the Canadian Cancer Society, it is estimated that 11,700 Canadians will be diagnosed with non-Hodgkin lymphoma. 3,100 Canadians will die from non-Hodgkin lymphoma. 6,600 men will be diagnosed with non-Hodgkin lymphoma and 1,800 will die from it. 5,100 women will be diagnosed with non-Hodgkin lymphoma and 1,300 will die from it.
Market Segmentation
By Test Type
Sentinel lymph node Biopsy
Blood Tests
CT Scan & PET Scan
Others
By Disease Type
Non-Hodgkin lymphoma
Hodgkin lymphoma
By End-User
Hospitals
Diagnostic Centers
Research and Educational Institutions
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global lymph cancer testing market include GE Healthcare, Siemens Healthineer, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, and Bio-Rad Laboratories among others.
Key Developments
In March 2024, SCOR announced the launch of the Vitae Lymphoma Risk Calculator, a new addition to the Group’s biometric risk calculator series that aims to expand protection coverage to people with cancer and other critical diseases.
In November 2023, Roswell Park launched an advanced, high-speed blood cancer test. PanHeme is the test that uses next-generation gene sequencing technology to diagnose blood cancers like leukemia, and lymphoma and identify mutations in hundreds of genes in under 72 hours, a dramatic improvement from the three- to four-week wait time for current molecular testing.
Why Purchase the Report?
To visualize the global lymph cancer testing market segmentation based on test type, disease type, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global lymph cancer testing market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global lymph cancer testing market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Disease Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Lymph Cancers
4.1.1.2. Technological Advancements
4.1.1.3. Increasing Awareness among People
4.1.2. RestraintsRestrains
4.1.2.1. High Cost Associated with the Testing
4.1.2.2. Lack of Healthcare Infrastructure
4.1.2.3. Shortage of Skilled Professionals
4.1.2.4. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Test Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Sentinel Lymph Node Biopsy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Blood Tests
6.4. CT Scan and PET Scan
6.5. Others
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Non–Hodgkin Lymphoma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hodgkin Lymphoma
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Centers
8.4. Research and Educational Institutions
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. GE Healthcare *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Siemens Healthineers
11.3. Abbott Laboratories
11.4. Canon Medical Systems
11.5. Agilent Technologies
11.6. MDx Health
11.7. Beckman Coulter
11.8. Myriad Genetics
11.9. Ambry genetics
11.10. Bio-Rad Laboratories (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

GE Healthcare, 4.	Key Developments, Siemens Healthineers, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry genetics

표 목록 (Tables)

List of Tables

Table 1 Global Lymph Cancer Testing Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Lymph Cancer Testing Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Lymph Cancer Testing Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Lymph Cancer Testing Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Lymph Cancer Testing Market Value, By Test Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 7 Global Lymph Cancer Testing Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 9 Global Lymph Cancer Testing Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Lymph Cancer Testing Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Lymph Cancer Testing Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 14 North America Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 15 North America Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Lymph Cancer Testing Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 18 South America Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 19 South America Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Lymph Cancer Testing Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 22 Europe Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 23 Europe Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Lymph Cancer Testing Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Lymph Cancer Testing Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Lymph Cancer Testing Market Value, By Test Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Lymph Cancer Testing Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Lymph Cancer Testing Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Lymph Cancer Testing Market Value, By Country, 2022-2031 (US$ Million)

Table 33 GE Healthcare: Overview

Table 34 GE Healthcare: Product Portfolio

Table 35 GE Healthcare: Key Developments

Table 36 Siemens Healthineer: Overview

Table 37 Siemens Healthineer: Product Portfolio

Table 38 Siemens Healthineer: Key Developments

Table 39 Abbott Laboratories: Overview

Table 40 Abbott Laboratories: Product Portfolio

Table 41 Abbott Laboratories: Key Developments

Table 42 Canon Medical Systems: Overview

Table 43 Canon Medical Systems: Product Portfolio

Table 44 Canon Medical Systems: Key Developments

Table 45 Agilent Technologies: Overview

Table 46 Agilent Technologies: Product Portfolio

Table 47 Agilent Technologies: Key Developments

Table 48 MDx Health: Overview

Table 49 MDx Health: Product Portfolio

Table 50 MDx Health: Key Developments

Table 51 Beckman Coulter: Overview

Table 52 Beckman Coulter: Product Portfolio

Table 53 Beckman Coulter: Key Developments

Table 54 Myriad Genetics: Overview

Table 55 Myriad Genetics: Product Portfolio

Table 56 Myriad Genetics: Key Developments

Table 57 Ambry Genetics: Overview

Table 58 Ambry Genetics: Product Portfolio

Table 59 Ambry Genetics: Key Developments

Table 60 Bio-Rad Laboratories: Overview

Table 61 Bio-Rad Laboratories: Product Portfolio

Table 62 Bio-Rad Laboratories: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 2 Global Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 3 Global Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 4 Global Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 5 Global Lymph Cancer Testing Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Lymph Cancer Testing Market Y-o-Y Growth, By Test Type, 2023-2031 (%)

Figure 7 Sentinel lymph node Biopsy Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 8 Blood Tests Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 9 CT scan & PET Scan Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 10 Others Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 11 Global Lymph Cancer Testing Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)

Figure 12 Non-Hodgkin Lymphoma Disease Type in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 13 Hodgkin lymphoma Disease Type in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 14 Global Lymph Cancer Testing Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 15 Hospitals End-User in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 16 Diagnostic Centers End-User in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 17 Research and Educational Institutions End-User in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 18 Others End-User in Global Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 19 Global Lymph Cancer Testing Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 20 North America Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 21 North America Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 22 North America Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 23 North America Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 24 North America Lymph Cancer Testing Market Share, By Country, 2023 & 2031 (%)

Figure 25 South America Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 26 South America Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 27 South America Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 28 South America Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 29 South America Lymph Cancer Testing Market Share, By Country, 2023 & 2031 (%)

Figure 30 Europe Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 31 Europe Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 32 Europe Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 33 Europe Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 34 Europe Lymph Cancer Testing Market Share, By Country, 2023 & 2031 (%)

Figure 35 Asia-Pacific Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 36 Asia-Pacific Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 37 Asia-Pacific Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 38 Asia-Pacific Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 39 Asia-Pacific Lymph Cancer Testing Market Share, By Country, 2023 & 2031 (%)

Figure 40 Middle East and Africa Lymph Cancer Testing Market Value, 2022-2031 (US$ Million)

Figure 41 Middle East and Africa Lymph Cancer Testing Market Share, By Test Type, 2023 & 2031 (%)

Figure 42 Middle East and Africa Lymph Cancer Testing Market Share, By Disease Type, 2023 & 2031 (%)

Figure 43 Middle East and Africa Lymph Cancer Testing Market Share, By End-User, 2023 & 2031 (%)

Figure 44 GE Healthcare: Financials

Figure 45 Siemens Healthineer: Financials

Figure 46 Abbott Laboratories: Financials

Figure 47 Canon Medical Systems: Financials

Figure 48 Agilent Technologies: Financials

Figure 49 MDx Health: Financials

Figure 50 Beckman Coulter: Financials

Figure 51 Myriad Genetics: Financials

Figure 52 Ambry Genetics: Financials

Figure 53 Bio-Rad Laboratories: Financials

글로벌 림프암 검사 시장 – 2024년 – 2031년

Global Lymph Cancer Testing Market - 2024 - 2031